Galectin Therapeutics reported $-11.29M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Galectin Therapeutics USD -11.29M 1.64M Jun/2024
Gilead Sciences USD 2.68B 284M Mar/2026
Immunic USD -23.33M 2.67M Dec/2025
Incyte USD 324.17M 59.7M Mar/2026
Merck USD -1.88B 8.12B Mar/2026